Loading fund overlap…
14 of 214 unique stocks in common · Jaccard: 6.5%
A weighted portfolio overlap of 7.19% indicates a low overlap (mostly different holdings). This means that out of every ₹100 you invest across these two schemes, approximately ₹7.19 is allocated to the exact same companies at the same relative proportions. The schemes share 14 common holdings.
The largest overlapping asset in their portfolios is Aster DM Healthcare, which commands a weight of 1.32% in Back to Index and 2.02% in UTI Small Cap Fund. Holding both schemes increases your concentration in Aster DM Healthcare rather than expanding your diversification.
If the overlap is above 30%, it is typically because both schemes benchmark to the same index (e.g. Nifty 50 or Nifty LargeMidcap 250) or overlap in their top large-cap picks. To improve your portfolio's diversification, consider allocating one of these tranches to a category with lower structural correlation (such as a mid-cap, small-cap, or international equity fund).
| Stock | in Back | in UTI |
|---|---|---|
| Aster DM HealthcareHealthcare Services | 1.32% | 2.02% |
| Acutaas ChemicalsPharmaceuticals & Biotechnology | 0.95% | 2.45% |
| Sai Life SciencesPharmaceuticals & Biotechnology | 1.03% | 0.84% |
| Dr. Lal Path LabsHealthcare Services | 0.75% | 0.82% |
| Krishna Institute Of Medical SciencesHealthcare Services | 1.18% | 0.59% |
| Eris LifesciencesPharmaceuticals & Biotechnology | 0.58% | 1.54% |
| Vijaya Diagnostic CentreHealthcare Services | 0.39% | 1.32% |
| Metropolis HealthcareHealthcare Services | 0.36% | 1.12% |
| Anthem BiosciencesPharmaceuticals & Biotechnology | 0.33% | 0.46% |
| Marksans PharmaPharmaceuticals & Biotechnology | 0.33% | 1.59% |
| Jupiter Life Line HospitalsHealthcare Services | 0.33% | 0.39% |
| Caplin Point LaboratoriesPharmaceuticals & Biotechnology | 0.24% | 1.53% |
| Blue Jet HealthcarePharmaceuticals & Biotechnology | 0.11% | 0.46% |
| Orchid PharmaPharmaceuticals & Biotechnology | 0.07% | 0.45% |
Weighted overlap = Σ min(weight in fund A, weight in fund B) across shared stocks, from each fund's latest public monthly portfolio (as on May 2026). Equity holdings only, ISIN-verified. Not investment advice.